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Whole exome sequencing identifies mutational 
signatures of vitreoretinal lymphoma
Primary vitreoretinal lymphoma (VRL) is a rare intraoc-
ular malignancy that is closely related to primary central
nervous system lymphoma (PCNSL). Most cases of VRL
are comprised of high-grade diffuse large B-cell lymphoma
(DLBCL), which is aggressive and has a poor prognosis.1
Confirming the diagnosis of VRL is quite difficult.
Cytopathologic examination, the standard diagnostic pro-
cedure, suffers from very low sensitivity due to the limited
number of cells, preceding corticosteroid therapy, and the
rapid degeneration of lymphoma cells.1 The biological
background of VRL is largely unknown, therefore, under-
standing its genomic landscape could be the first step in
clarifying its pathogenesis, diagnosis, prognosis and treat-
ment. We investigated the mutational profile of VRL using
whole exome sequencing (WES) and evaluated the diag-
nostic value of WES in patients with suspected VRL.
Vitreous samples from nine patients with VRL (with six
samples of matched blood), and from four patients with
intermediate or posterior uveitis were obtained consecu-
tively between June 2018 and April 2019 at the Severance
Hospital. All vitreous samples were collected prospectively
by pars plana vitrectomy before chemotherapy. The diag-
nosis of VRL was made comprehensively based on cytol-
ogy of the vitreous or central nervous system (CNS) sam-
ples, laboratory results of the vitreous or CNS samples and
vitreoretinal findings. This prospective study was approved
by the Severance Hospital Institutional review board (4-
2018-0389). It was conducted in accordance with the
tenets of the Declaration of Helsinki. All samples on which
WES was performed had also been examined using stan-
dard cytology, interleukin (IL)-6 and IL-10 assays, and clon-
ality assays for immunoglobulin heavy chain (IGH) and
kappa light chain (IGK). The WES was performed using the
Twist Human Core Exome kit (Twist Bioscience, San
Francisco, CA, USA) and NovaSeq system (Illumina, San
Diego, CA, USA). Other experimental details are described
in the Online Supplementary Materials and Methods. 
All enrolled patients were human immunodeficiency
viruses-negative and immunocompetent. The specific eti-
ologies of uveitis included cytomegalovirus (CMV) retinitis
(Control 1 and 3), acute retinal necrosis (Control 2), and
sarcoidosis (Control 4). Detailed clinical information of the
VRL patients is summarized in Table 1. In two patients
(Case 8 and 9), PCNSL invaded into the vitreo-retina. In
the remaining seven patients, lymphoma occurred in the
vitreo-retina primarily without CNS involvement at the
time of diagnosis. Three of the nine patients was diag-
nosed by cytopathologic examination. In all patients, the
IL-10 to IL-6 ratios were greater than 1, and the absolute
IL-10 levels were greater than 150 pg/mL. Monoclonal




Table 1. Demographics, clinical findings, and results of diagnostic vitrectomy in patients with vitreoretinal lymphoma.
No         Sex       Age       Previous   Germline-Somatic   Right/    Vitreoretinal        Pathology               IL-6         IL-10           Ig H                 Ig K 
                       (years)    diagnosis           paired              Left           finding            (Vitreous)            (pg/mL)   (pg/mL)    clonality         clonality
                                     of  PCNSL          sample              eye                                                                                                                              
1                F             53                No                      (+)                    Left            Vitreous               Atypical                     12.3           290.0      Monoclonal         Polyclonal
                                                                                                                                opacity           large lymphoid
                                                                                                                                                      cells, suspecting
                                                                                                                                                            lymphoma                                                               
2                F             63                No                      (+)                   Right           Vitreous               Atypical                    128.6         2,606.9     Monoclonal       Monoclonal
                                                                                                                                opacity           large lymphoid 
                                                                                                                                                      cells, suspecting
                                                                                                                                                            lymphoma                                         
3               M            66                No                      (+)                    Left            Vitreous               Atypical                      6.4            738.0     Inconclusive     Inconclusive
                                                                                                                                opacity           large lymphoid 
                                                                                                                                                      cells, suspecting 
                                                                                                                                                            lymphoma                                                               
4               M            67                No                      (+)                   Right           Sub-RPE         Unsatisfactory              376.4         2,780.0     Monoclonal       Monoclonal
                                                                                                                             infiltration                                                                                              
5               M            85                No                      (+)                    Left            Sub-RPE              Negative                   233.3          864.4     Inconclusive      Monoclonal
                                                                                                                             infiltration       for malignancy                                                           
6                F             53                No                       (-)                   Right           Vitreous         Unsatisfactory               14.6           521.9      Monoclonal       Monoclonal
                                                                                                                                opacity                                                        
7               M            77                No                       (-)                   Right           Vitreous              Negative                    24.2           798.8        Polyclonal         Monoclonal
                                                                                                                                opacity           for malignancy                  
8               M            81               Yes                     (+)                   Right           Vitreous         Unsatisfactory               72.5           251.2      Monoclonal      Inconclusive
                                                                                                                                opacity                        
9                F             48               Yes                      (-)                    Left            Vitreous              Negative                   232.5         1,411.6      Polyclonal         Monoclonal
                                                                                                                                opacity           for malignancy                  
No: number; PCNSL: primary central nervous system lymphoma; IL: interleukin; Ig H: immunoglobulin heavy chain; Ig K: immunoglobulin kappa light chain; F: female; 
M: male; RPE: retinal pigment epithelium.
The overall frequency of the identified somatic muta-
tions are depicted in Figure 1A. Mutations in the MYD88
gene were detected in all nine patients. The known somat-
ic hypermutation (SHM) associated genes, including PIM1
and IGLL5, were also frequently mutated.2 In contrast,
genes that are known to be frequently mutated in PCNSL,
such as CD79B, were not frequently mutated in our
cohort. In MYD88 gene, the L265P mutation was detected
in seven patients (7 of 9, 77.8%; see the Online
Supplementary Figure S1) and P258L and V217F were found
in the other two patients (Figure 1B), with a variant allele
fraction ranging from 0.28 to 0.89. The L265P mutation
was the most common single mutation in our cohort with
a similar frequency to that in previous report (69%).3
P258L and V217F are somatic mutations that have been
previously reported in cancers including VRL and
DLBCL.3,4 All of the mutations were located in the known
mutational hot spot, Toll/IL-1 receptor (TIR) domain,
which interacts with the Toll-like receptor (TLR) (Figure
1B). Although the characteristic MYD88 mutations were
shared between VRL and PCNSL patients, the mutation
was significantly more frequent in our VRL patients than
it was in PCNSL (100% vs. 62.8%; P=0.0263).2,5-7 The
CD79B mutation is another hallmark of PCNSL.2,5,6 The
mutation in CD79B was less frequently identified in our
VRL patients than it was in the PCNSL cohort (2 of 9;
22.2%) (22.2% vs. 40.0%; P=0.473). The Y197D and
L200Q mutations in CD79B were identified. All detected
mutations were located on the immunoreceptor tyrosine-
based activation motif (ITAM) domain. PIM1 point muta-
tions were identified in eight patients. Each patient har-
bored 1 to 22 point mutations in the PIM1 gene (Online
Supplementary Table S1). Point mutations, as well as
increased expression, of PIM1 gene were associated with
adverse effects in patients with the activated B-cell (ABC)
type DLBCL.8 We also identified specific point mutations
of PIM1 gene that were associated with drug resistance in
our patients (Online Supplementary Table S1).8 Historically,
IGLL5 had not been described as being frequently mutated
in B-cell lymphomas. However, several recent studies have
suggested a relative high frequency of IGLL5 mutation,
with associated biological importance, in DLBCL and
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Figure 1. Analysis of whole exome sequencing data in patients with vitreoretinal lymphoma. (A) Recurrently mutated genes identified more than three patients.
Columns represent patients (VRL: n=9; uveitis: n=4) and rows represent genes. Box color-coding indicates the type of mutation or genomic alteration. Known
somatic hypermutation associated genes are displayed in red. The bar graph on the right represents the proportion of mutated cases in this study. (B) Somatic
mutations in MYD88. The relative positions and case number of somatic mutations are shown in the predicted protein sequences of MYD88. All mutations were
located in the Toll/interleukin-1 receptor homology (TIR) domain.  (C) The percent of mutated cases in VRL (black bars) and in PCNSL cohorts from four different
studies (red bars; data from ref. 2, 5-7). Asterisks indicate statistical significance. (D) Overlaps in recurrently mutated genes are detected in total DLBCL, PCNSL,
and our VRL cohort. The Venn diagram depicts the top 30 frequently mutated genes from five other DLBCL or PCNSL studies (ref. 2, 5-7 and 12), and the present




CLL.9 Although IGLL5 is known to play a critical role in B-
cell development, little else is known about its function.
Therefore, further studies regarding its potential role in
lymphomagenesis would be needed. A germline heterozy-
gous ERCC6 splice-site mutation (c.1527-2A>G) was iden-
tified in one patient (Case 8, Online Supplementary Figure
S2). Germline genes that may predispose a patient to lym-
phoma include DNA repair genes.10 ERCC6 is known to
play a critical role in DNA repair and prior studies found
that disruption of the function of ERCC6 increases cancer
susceptibility.11 As DNA repair genes, such as BRCA1 and
PALB2, are related to cancer predisposition even in the
presence of a mono-allelic mutation, ERCC6 germline
mutations may be associated with malignancy. Regardless,
this hypothesis requires further investigation.
The mutated genes in patients with VRL were similar to
those in patients with PCNSL. Still there were some differ-
ences in specific mutation frequencies. For instance, VRL
had a significantly higher rate of MYD88 and IGLL5muta-
tions than PCNSL (P=0.0263 and P=0.0001, respectively;
Figure 1C). Among the list of frequently mutated genes in
VRL and PCNSL, SHM-associated genes such as PIM1,
IGLL5, BTG1, and BTG2 were included.2,12 Using copy-
number variation (CNV) analysis, we identified biallelic or
monoallelic deletion of CDKN2A in 6 of the 9 patients
(66.7%; Online Supplementary Figure S3). In contrast, we
did not detect the TP53 sequence variation or CNV, which
resembled the reported features of PCNSL and primary
testicular lymphomas.13 As a subtype of DLBCL, most of
the frequently mutated genes in VRL were identical to
those of DLBCL. These mutations included MYD88 and
SHM-associated genes (Figure 1D). However, there were
larger differences in the frequencies of mutations between
DLBCL and VRL than there were between VRL and
PCNSL. According to the genetic subtypes of DLBCL
reported by Schmitz et al.,12 it could be speculated that VRL
could be classified into the MCD subtype (defined based
on co-occurrence of MYD88 L265P and CD79Bmutations)
based on a high frequency of the characteristic MYD88
mutation and similarity in pattern of other gene mutations
(Online Supplementary Figure S4). 
The genetic profiling of VRL can facilitate precise thera-
py. For instance, Ibrutinib is a molecular targeted drug for
BTK that has been used in the treatment of MYD88-pos-
tive B-cell lymphomas. However, the primary sensitivity
or resistance to this drug is influenced by the presence of
mutations beyond MYD88 alone and concurrent muta-
tions in CXCR4, CD79A, CD79B, or PIM1 have been asso-
ciated with drug sensitivity and resistance.8,14 In addition,
an alternative type of MYD88 can serve as a predictive
marker of BTK inhibition.13Therefore, it is clinically impor-
tant not only to evaluate well-known genes, but also the
whole exome to optimize precise therapy. VRL typically
masquerades as uveitis. Its diagnosis remains difficult, and
is often delayed for several months.1 However, rapid diag-
nosis of VRL is critical for its appropriate treatment. The
standard diagnosis of VRL involves the cytologic evalua-
tion of malignant lymphoma cells, however, false-nega-
tives are common.1 Therefore, complementary diagnostic
tools evaluating the IL-10 to IL-6 ratio or immunoglobulin
clonality have also been used.1 Recently, the allele specific
PCR for the MYD88 L256P mutation and specific
microRNA have demonstrated high diagnostic power.3,15
However, evaluating proteins such as IL-10 or microRNA
is not a confirmatory diagnostic tool because they illus-
trate the clinical phenomenon rather than identifying the
cancer itself. In addition, the immunoglobulin clonality
assay is susceptible to false positives due to the difficulty
of acquiring sufficient DNA and the possibility of contam-
inating reactive cells. Given the existing diagnostic chal-
lenges, we confirmed the utility of WES in making the
diagnosis of VRL and in mutational profiling. Considering
feasibility and cost-effectiveness in routine clinical prac-
tice, however, a smaller targeted gene panel testing based
on frequently mutated genes in this WES study would be
easier, cheaper, and a more readily available way to allow
a rapid diagnosis and a higher diagnostic yield.
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